Moneycontrol PRO
Black Friday Sale
Black Friday Sale
HomeNewsBusinessMarketsQ4FY21 earnings | Can COVID-19 puncture the hopes of a strong quarter?

Q4FY21 earnings | Can COVID-19 puncture the hopes of a strong quarter?

The daily cases in the second wave have already surpassed the peak of the first wave, forcing many state governments to introduce fresh restrictions.

April 12, 2021 / 09:58 IST

The fourth quarter earnings (Q4 FY21) of India Inc will start to trickle in from April 12 with IT heavyweight TCS announcing its Q4 scorecard on the same day.

After two consecutive quarters of strong earnings and upgrades, analysts, brokerages and market participants expect healthy earnings this time too which could trigger further upgrades in consensus estimates for Nifty and Sensex earnings for FY22 and FY23.

However, some companies may see pressure on margins due to the rise in commodity prices.

"The earnings season is likely to be healthy and could end with further upgrades in consensus estimates for Nifty/Sensex earnings for FY22 and FY23," Gaurav Dua, SVP and Head - Capital Market Strategy at Sharekhan told Moneycontrol.

"However, unlike the past two quarters, the rising commodity prices would put pressure on margins across many sectors in the March quarter results and consequently, limit the growth in earnings in some key sectors," said Dua.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
The COVID threat

March quarter earnings will be among the top triggers that will dictate the trend of the market in the near term. However, can a surge in COVID-19 cases, which can potentially derail the economic recovery, hit earnings too?

The daily cases in the second wave have already surpassed the peak of the first wave, forcing many state governments to introduce fresh restrictions.

Harsha Upadhyaya, CIO, Kotak Mutual Fund told CNBC-TV18 that earnings are going to be very strong given that we have a favourable base as well we have seen sequential improvement during the January-March quarter.

"The earnings will not really pull down the markets. Over the next couple of months, we will see economic momentum coming back and vaccination also gaining momentum and that should help the markets in the

medium-term," said Upadhyaya.

In a broader sense, the March quarter earnings will come on a stronger note, despite some disruption in the last month of the quarter due to COVID-19.

"We are not too concerned about the earnings. Any disruption is a blessing in disguise for great companies through market share gains hence we are looking forward to the next two three years despite the second wave of COVID-19," Rakshit Ranjan, Portfolio Manager, Marcellus Investment Managers told CNBC-TV18.

Healthy Q4 in the offing

As per domestic brokerage firm Motilal Oswal Financial Services, Nifty may post a healthy two-year profit CAGR of 14 percent over Q4FY19–Q4FY21.

"Over 4QFY19–4QFY21, Nifty should post a CAGR of 6 percent, 10 percent, 12 percent and 14 percent," Motilal said.

As per the brokerage, Nifty sales should grow 18 percent, EBITDA 26 percent, PBT 77 percent and PAT should grow 65 percent YoY in Q4FY21E.

The brokerage firm believes metals, private banks and NBFCs, IT, autos and consumer staples and durables will be the top drivers of the Q4FY21 performance.

"Metals, private banks and automobiles are expected to drive nearly 60 percent of the incremental Q4FY21 PAT growth. Consumer durables, cement, healthcare, consumer staples and technology are likely to post earnings growth of 62 percent, 59 percent, 43 percent, 19 percent and 16 percent year-on-year (YoY), respectively," Motilal said.

FY21E/FY22E Nifty EPS estimates have seen minor tweaks. As per Motilal, Nifty's FY21 EPS has seen a marginal 1 percent cut to Rs 533 against the previous Rs 541.

However, Nifty FY22/FY23 EPS is stable at Rs 726/Rs 861 (prior: Rs 719/Rs 857), Motilal pointed out.

Despite the unprecedented challenges of FY21, the Nifty should end the year with healthy 13 percent EPS growth, Motilal Oswal believes.

Another brokerage firm Kotak Securities expects a strong YoY increase in the net income of automobiles, banks, metals & mining and oil & gas.

Kotak expects net profits for Sensex to increase 55 percent YoY and 6 percent QoQ and for the Nifty50 to increase 125 percent YoY and 8 percent QoQ.

Kotak estimates EPS of Sensex at Rs 2,197 for FY22 and Rs 2,596 for FY23 and of the Nifty50 index at Rs 688 for FY22 and Rs 803 for FY23.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Nishant Kumar
first published: Apr 12, 2021 09:58 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347